SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: D.Right who wrote (1378)5/19/1998 8:51:00 AM
From: arnie h  Read Replies (1) of 2173
 
Dear D.: Thanks for the clarification. The matter of weakening response is fundamental although the explanation offered by AMLN for it in the case of TypeII has seemed reasonable. Yet, I've wondered whether there may be fundamental forces at work that do lead to "less bounce to the ounce" in time. I remember in the early days of monoclonal antibodies that some team had developed a silver bullet that honed in on a tumor cell receptor, only to find the tumor cell tucked the receptor inside the membrane a few generations later. Do you have any insights into possible mechanisms the body may bring to bear that will reduce the effect of pramlinitide over time?

The stock price action is following the normal path, as I discussed a couple of weeks ago. It should start to hold in the mid-4's. If so, it would be another positive sign that things are heading up.

Regards,
Arnie
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News